Patents Assigned to Ipsen Pharma S.A.S.
  • Publication number: 20200095281
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Patent number: 10543249
    Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 28, 2020
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Ruth Bielsa Guivernau, Roland Cherif-Cheikh, Julie Fournes, Daniel Martinez Lorente, Anne Petit, Joël Richard
  • Publication number: 20200017548
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20190248861
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 15, 2019
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Publication number: 20190167754
    Abstract: Process for the preparation of an injectable pharmaceutical composition for the sustained release of somatostatin analogues. Composition prepared according to such a process.
    Type: Application
    Filed: December 26, 2018
    Publication date: June 6, 2019
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Martin MONTES, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Publication number: 20190111105
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Publication number: 20190062374
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: November 12, 2018
    Publication date: February 28, 2019
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Patent number: 10206968
    Abstract: A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 19, 2019
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Publication number: 20180305406
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: July 9, 2018
    Publication date: October 25, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20180303899
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: November 2, 2017
    Publication date: October 25, 2018
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Patent number: 9975880
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): These compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: May 22, 2018
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Serge Auvin, Christophe Lanco, Oliver Dutruel, Qi Chao, Kaichun Gu
  • Publication number: 20180118784
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: August 29, 2017
    Publication date: May 3, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
  • Publication number: 20180105557
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Patent number: 9918967
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 20, 2018
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Pierre-Etienne Chabrier de Lassauniere, Michel Auguet, Brigitte Spinnewyn
  • Patent number: 9850280
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 26, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20170362275
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 21, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Patent number: 9827286
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 28, 2017
    Assignees: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Publication number: 20170304403
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. TAYLOR, Rakesh DATTA, Michael DeWitt CULLER
  • Patent number: 9777039
    Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 3, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Eric Ferrandis
  • Patent number: 9758549
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 12, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock